Solid Biosciences Inc. (SLDB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Current obligations | 28.58M USD | Liabilities, Current |
| Cash and equivalents | 159.39M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 218.28M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $28.58M | $159.39M | $218.28M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $30.28M | $297.10M | $83.58M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $33.47M | $59.90M | $127.95M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $36.34M | $61.36M | $174.78M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $29.85M | $138.93M | $129.18M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $28.78M | $210.63M | $96.29M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $30.26M | $80.23M | $68.69M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $22.85M | $64.39M | $106.72M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $14.69M | $95.85M | $94.41M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $14.34M | $117.57M | $88.49M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $14.52M | $74.02M | $49.63M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $15.82M | $49.04M | $93.85M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $15.87M | $91.57M | $68.62M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $20.29M | $164.65M | $20.86M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $22.51M | $155.38M | $58.34M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $16.93M | $48.79M | $93.37M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $21.72M | $54.31M | $108.57M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $21.74M | $129.71M | $50.34M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $23.60M | $119.14M | $88.64M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $22.54M | $109.68M | $120.08M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $22.55M | $200.61M | $48.35M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $22.83M | $268.50M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $24.48M | $154.74M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $14.77M | $24.80M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $13.17M | $40.44M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $12.88M | $53.19M | $400.00K | (m) | (m) | (m) |
| 2019-12-31 | (m) | $18.28M | $76.04M | $7.48M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $16.75M | $94.72M | $10.94M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $13.67M | $51.84M | $15.55M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $14.57M | $53.99M | $40.75M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $12.48M | $86.37M | $36.10M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $10.64M | $129.14M | $16.23M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $8.68M | $145.82M | $16.93M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $9.93M | $164.77M | $17.61M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $11.27M | $52.08M | $17.01M | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $15.02M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $32.72M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $29.27M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $7.68M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |